Syndax Pharmaceuticals SNDX Cash Flow Statement (2015-2026)

NASDAQ SNDX
$20.58 -0.10 (-0.48%)
As of: Sep 4, 2026 · 2:23 PM EDT
Reported Financials

Syndax Pharmaceuticals Quarterly Cash Flow Statement

Periods 46 quarters
Latest Jun 2026

Syndax Pharmaceuticals reported cash from operations of -$30.27M and free cash flow of -$30.27M for the quarter ended Jun 2026, up 65.5% year over year. This cash flow statement covers 46 quarters of results from Mar 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-20.60M95.85M-38.19M-39.11M-35.11M-39.09M-45.59M-49.95M-51.08M-72.42M-80.58M-74.36M-84.16M-89.13M-83.39M-63.41M-52.16M-58.22M-34.64M-36.25M
Share-based CompensationStock Comp.
3.38M3.93M3.48M3.94M4.36M4.24M6.24M8.06M8.32M8.33M8.90M9.90M11.93M12.30M10.38M13.79M12.08M11.25M12.05M14.01M
Gains from Investment SecuritiesGains Investment
Cash from OperationsCash from Ops.
-24.94M100.71M-41.93M-40.31M-28.54M-22.89M-39.23M-35.37M-44.65M-41.35M-83.55M-71.64M-62.32M-57.39M-95.16M-87.80M-70.53M-69.49M-50.34M-30.27M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
-0.17M-0.17M0.05M0.27M1.04M2.02M3.97M3.72M3.66M3.46M3.82M3.65M3.06M2.94M3.60M3.21M2.41M1.53M0.86M0.71M
Amortization of Deferred ChargesAmort. Deferred Charges
0.03M0.11M0.06M0.06M-0.00M0.06M0.30M
Change in Working Capital
Change in ReceivablesChange Receivables
8.56M4.54M2.08M1.89M-3.90M-0.07M6.07M3.51M-6.08M4.09M8.12M3.73M5.95M12.59M-6.14M13.21M
Change in InventoryChange Inventory
0.37M4.19M12.92M7.18M7.80M2.06M-1.84M
Change in Account PayablesChange Payables
1.50M0.55M2.56M-1.79M0.68M-2.76M3.71M2.92M-4.93M3.91M-1.15M2.76M-6.67M6.73M-1.58M7.31M-3.53M2.75M-5.74M-5.97M
Change in Accured ExpensesChange Accured Exp.
1.90M0.64M3.86M-1.54M-3.86M10.97M-9.17M2.38M14.16M7.50M-6.71M-6.84M21.04M11.65M-2.53M17.90M1.10M25.70M-28.35M18.77M
Other Working Capital ChangesOther WC Changes
-12.38M
Investing Activities
Capital ExpendituresCapex
0.13M0.06M
Change in Acquisitions & DivestmentsChange Acquisitions
89.58M45.40M50.45M72.42M72.82M113.25M81.50M154.91M122.80M113.00M67.99M61.75M100.20M107.34M104.68M133.60M103.00M144.75M77.78M69.00M
Cash from Investing ActivitiesCash from Investing
26.63M-59.96M8.18M-49.95M-6.79M-137.63M19.91M73.91M40.08M-16.29M-99.40M61.75M86.85M-268.97M94.14M41.89M72.43M81.58M38.39M-16.91M
Financing Activities
Other financing activitiesOther financing
0.10M3.02M0.47M2.23M7.40M1.40M2.28M1.15M1.59M0.11M1.86M0.44M2.56M3.14M0.55M0.47M5.81M5.31M7.46M8.76M
Cash from Financing ActivitiesCash from Financing
1.71M109.78M0.56M21.72M-13.53M163.50M2.47M1.32M1.85M258.48M2.17M0.68M3.10M347.43M0.93M0.55M6.28M5.92M7.92M252.77M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
1.60M3.02M3.80M2.89M3.98M
Net Equity Issued and RepurchasedNet Equity Issued
81.20M142.54M215.96M
Additional items
Change in Cash
3.39M150.53M-33.19M-68.53M-48.86M2.98M-16.84M39.86M-2.73M200.84M-180.78M-9.22M27.62M21.06M-0.09M-45.36M8.17M18.01M-4.04M205.58M
Free Cash FlowFCF
-24.94M100.71M-41.93M-40.31M-28.54M-22.89M-39.23M-35.37M-44.65M-41.35M-83.55M-71.64M-62.32M-57.39M-95.16M-87.80M-70.67M-69.54M-50.34M-30.27M
Net Cash FlowNCF
3.39M150.53M-33.19M-68.53M-48.86M2.98M-16.84M39.86M-2.73M200.84M-180.78M-9.22M27.62M21.06M-0.09M-45.36M8.17M18.01M-4.04M205.58M